ENALAPRIL MALEATE

Post-LOE

enalapril maleate

Bristol Myers Squibb

ANDAORALSOLUTION

Approved

Feb 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

ENALAPRIL MALEATE (enalapril maleate) by Bristol Myers Squibb is enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension, to lower blood pressure in adults, children older than one month [see pediatric use ( ) and 22 more indications. First approved in 2022.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion…

Indications (22)

Worked on ENALAPRIL MALEATE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.